-+ 0.00%
-+ 0.00%
-+ 0.00%

XBIOTECH: PHASE II STUDY FAILED TO MEET PRIMARY ENDPOINT AMID SUBSTANTIAL IRREGULARITIES THAT MAKE UNEQUIVOCAL INTERPRETATION OF FINDINGS DIFFICULT

Reuters·12/23/2024 14:00:18

Please log in to view news